Reading room · November 7, 2026
Read a general safety notice with precision
Understand what the FDA's NAD+ compounding notice says, what it does not establish about a particular provider and which questions it can help you bring to a clinician.
Educational and promotional content. CoreAge Rx is a featured commercial provider. No independent medical review or firsthand product testing is claimed.
Identify the scope of the notice
FDA has warned about using unsuitable food-grade NAD+ ingredients in sterile compounding and described reported adverse reactions after NAD+ injections consistent with endotoxin contamination. This is general regulatory context. It should not be rewritten as proof that CoreAge Rx or one of its pharmacies supplied a contaminated product or violated a requirement.
Keep approval status separate
CoreAge Rx describes its offered preparation as compounded. Compounded medicines do not receive FDA premarket approval, and the existence of a prescription process does not convert them into approved products. FDA says compounded drugs should be used only when an FDA-approved drug cannot meet a patient's medical needs. Ask the clinician to explain the proposed care in that context, including the relevant evidence limitations.
Use the notice to prepare questions
Ask who dispenses the proposed product, who provides its instructions and how to raise a concern about the preparation. These are questions for the treating team and pharmacy, not conclusions this guide can supply from a webpage. We have not tested intake, prescribing or fulfillment. Our commercial support for CoreAge Rx does not change the notice's scope, establish an expected benefit or resolve your individual suitability. Keep the answers alongside the product name and the provider's written terms before deciding.